Spironolactone

• CAT Number: A000654
• CAS Number: 52-01-7
• Molecular Formula: C24H32O4S
• Molecular Weight: 416.6
• Purity: ≥95%
• Target: Androgen Receptor
• Solubility: >18mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
• InChIKey: LXMSZDCAJNLERA-ZHYRCANASA-N
• SMILES: CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C

Spironolactone is a medication primarily used to treat fluid build-up due to heart failure, liver scarring, or kidney disease. Other uses include high blood pressure, low blood potassium that does not improve with supplementation, early puberty, excessive hair growth in women, and as a component of hormone replacement therapy for trans women.

Reference

1: Fershko AA, Neely JA, Calvo AR. Agranulocytosis Associated With Spironolactone
Therapy: A Case Report. World J Oncol. 2011 Oct;2(5):259-261. doi:
10.4021/wjon356w. Epub 2011 Oct 28. PubMed PMID: 29147257; PubMed Central PMCID:
PMC5649688.

2: Langote A, Hiremath S, Ruzicka M, McCormick BB. Spironolactone is effective in
treating hypokalemia among peritoneal dialysis patients. PLoS One. 2017 Nov
10;12(11):e0187269. doi: 10.1371/journal.pone.0187269. eCollection 2017. PubMed
PMID: 29125879.

3: Kleppe MS, Haskell RJ, Bogner RH. Biorelevant Media Slows the
Solution-Mediated Phase Transformation of Amorphous Spironolactone. J Pharm Sci.
2017 Nov 6. pii: S0022-3549(17)30782-7. doi: 10.1016/j.xphs.2017.10.041. [Epub
ahead of print] PubMed PMID: 29122582.

4: Wu VC, Wu CH, Yang YW, Huang KH, Chang CH, Yang SY, Lin YH, Wu KD; NRPB Kidney
Consortium. The therapeutic effect of bromocriptine in combination with
spironolactone in patients with primary aldosteronism: a hypothesis generating
pilot study. Oncotarget. 2017 Sep 6;8(44):77609-77621. doi:
10.18632/oncotarget.20670. eCollection 2017 Sep 29. PubMed PMID: 29100412; PubMed
Central PMCID: PMC5652803.

5: Lee JH, Lee SC, Kim H, Lee CS. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL
SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF
NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2017 Oct 30. doi:
10.1097/IAE.0000000000001913. [Epub ahead of print] PubMed PMID: 29095358.

6: Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S, Liu Q. Spironolactone versus
observation in the treatment of acute central serous chorioretinopathy. Br J
Ophthalmol. 2017 Oct 31. pii: bjophthalmol-2017-311096. doi:
10.1136/bjophthalmol-2017-311096. [Epub ahead of print] PubMed PMID: 29089356.

7: Elseweidy MM, Askar ME, Elswefy SE, Shawky M. Nephrotoxicity Induced by
Cisplatin Intake in Experimental Rats and Therapeutic Approach of Using
Mesenchymal Stem Cells and Spironolactone. Appl Biochem Biotechnol. 2017 Oct 17.
doi: 10.1007/s12010-017-2631-0. [Epub ahead of print] PubMed PMID: 29043663.

8: Al-Aboudi A, Kana/’an BM, Zarga MA, Bano S, Atia-Tul-Wahab, Javed K, Choudhary
MI. Fungal biotransformation of diuretic and antihypertensive drug spironolactone
with Gibberella fujikuroi, Curvularia lunata, Fusarium lini, and Aspergillus
alliaceus. Steroids. 2017 Oct 14;128:15-22. doi: 10.1016/j.steroids.2017.10.003.
[Epub ahead of print] PubMed PMID: 29037584.

9: Elinoff JM, Chen LY, Dougherty EJ, Awad KS, Wang S, Biancotto A, Siddiqui AH,
Weir NA, Cai R, Sun J, Preston IR, Solomon MA, Danner RL. Spironolactone-induced
Degradation of the TFIIH Core Complex XPB Subunit Suppresses NF-κB and AP-1
Signaling. Cardiovasc Res. 2017 Sep 27. doi: 10.1093/cvr/cvx198. [Epub ahead of
print] PubMed PMID: 29036418.

10: Funder JW. Spironolactone in cardiovascular disease: an expanding universe?
F1000Res. 2017 Sep 22;6:1738. doi: 10.12688/f1000research.11887.1. eCollection
2017. Review. PubMed PMID: 29034087; PubMed Central PMCID: PMC5615771.